Deal Library / Pharma BD Deal Intelligence

Cardiovascular Deals

The Pharma Closeout tracks 83 deals, $769.8B in disclosed deal value, 55 with a post-close Outcome Score for Cardiovascular.

Median Critic Score: 75  ·  Median Outcome Score: 70

Best outcome: Pfizer Inc. / FoldRx Pharmaceuticals (99)  ·  Weakest outcome: Daiichi Sankyo Company, Limited / Ranbaxy Laboratories Limited (14)

All 83 deals

• Pfizer Inc. / FoldRx Pharmaceuticals — 2010 · Worked — the deal delivered on its rationale.
• Abbott Laboratories / Knoll Pharmaceuticals (BASF Pharma) — 2000 · $6.9B · Worked — the deal delivered on its rationale.
• Astra AB / Zeneca Group plc — 1998 · $35.0B · Worked — the deal delivered on its rationale.
• Merck & Co. Inc. / Acceleron Pharma Inc. — 2021 · $11.5B · Worked — the deal delivered on its rationale.
• Johnson & Johnson / Actelion Ltd — 2017 · $30.0B · Worked — the deal delivered on its rationale.
• Eli Lilly and Company / Boehringer Ingelheim GmbH — 2011 · $444M · Worked — the deal delivered on its rationale.
• Novo Nordisk A/S / Dicerna Pharmaceuticals, Inc. — 2019 · $3.3B · Worked — the deal delivered on its rationale.
• The Medicines Company / Alnylam Pharmaceuticals Inc. — 2013 · Worked — the deal delivered on its rationale.
• Eli Lilly and Company / ICOS Corporation — 2006 · $2.3B · Worked — the deal delivered on its rationale.
• Pfizer Inc. / Wyeth — 2009 · $68.0B · Worked — the deal delivered on its rationale.
• Sanofi SA / Synthelabo S.A. — 1998 · $11.0B · Worked — the deal delivered on its rationale.
• Pfizer Inc. / Warner-Lambert Company — 2000 · $90.0B · Worked — the deal delivered on its rationale.
• Bristol-Myers Company / Squibb Corporation — 1989 · $16.0B · Worked — the deal delivered on its rationale.
• Abbott Laboratories / St. Jude Medical — 2016 · $30.5B · Worked — the deal delivered on its rationale.
• Sanofi-Synthelabo SA / Aventis SA — 2004 · $65.0B · Worked — the deal delivered on its rationale.
• Bayer AG / BlueRock Therapeutics — 2002 · $600M · Worked — the deal delivered on its rationale.
• Genzyme General (Genzyme Corporation) / GelTex Pharmaceuticals Inc. — 2000 · $1.0B · Worked — the deal delivered on its rationale.
• AstraZeneca PLC / CinCor Pharma Inc. — 2023 · $1.8B · Worked — the deal delivered on its rationale.
• Johnson & Johnson / Shockwave Medical — 2024 · $13.1B · Worked — the deal delivered on its rationale.
• Bristol-Myers Squibb Company / MyoKardia Inc. — 2020 · $13.1B · Worked — the deal delivered on its rationale.
• Novartis AG / Anthos Therapeutics — 2025 · $3.1B · Largely worked — most objectives met.
• Johnson & Johnson / Abiomed Inc. — 2022 · $16.6B · Largely worked — most objectives met.
• Rhone-Poulenc S.A. / Hoechst AG — 1998 · $21.2B · Largely worked — most objectives met.
• AstraZeneca PLC / Ionis Pharmaceuticals, Inc. — 2021 · $4.2B · Largely worked — most objectives met.
• Hoechst AG / Marion Merrell Dow Inc. — 1995 · $7.1B · Largely worked — most objectives met.
• Roche Holding AG / Alnylam Pharmaceuticals Inc. — 2023 · $2.8B · Largely worked — most objectives met.
• AstraZeneca PLC / ZS Pharma Inc. — 2015 · $2.7B · Largely worked — most objectives met.
• Novartis AG / Shanghai Argo Biopharmaceutical Co. Ltd. — 2024 · $4.2B · Largely worked — most objectives met.
• Merck & Co. Inc. / Schering-Plough Corp. — 2009 · $41.1B · Largely worked — most objectives met.
• Novartis AG / The Medicines Company — 2002 · $9.7B · Largely worked — most objectives met.
• Sekisui Chemical Co., Ltd. / Genzyme Diagnostic Products business — 2010 · $265M · Largely worked — most objectives met.
• Merit Medical Systems / BIOSPHERE MEDICAL INC — 2010 · $96M · Largely worked — most objectives met.
• Gilead Sciences Inc. / CV Therapeutics Inc. — 2009 · $1.4B · Largely worked — most objectives met.
• Gilead Sciences Inc. / Myogen Inc. — 2006 · $2.5B · Largely worked — most objectives met.
• Bayer AG / Arvinas, Inc. — 2019 · $1.0B · Mixed — partial payoff, real shortfalls.
• Sanofi SA / Regeneron Pharmaceuticals, Inc. — 2015 · $2.2B · Mixed — partial payoff, real shortfalls.
• Bayer AG / Merck & Co. Inc. — 2014 · $14.2B · Mixed — partial payoff, real shortfalls.
• GSK plc / Suzhou Siran Biotechnology Co., Ltd. — 2026 · $1.1B · Mixed — partial payoff, real shortfalls.
• Merck & Co. Inc. / Schering-Plough Corporation (joint venture, ezetimibe) — 2000 · Mixed — partial payoff, real shortfalls.
• Bayer AG / Asklepios BioPharmaceuticals — 2020 · $2.0B · Mixed — partial payoff, real shortfalls.
• HeartWare / WorldHeart — 2012 · $8M · Mixed — partial payoff, real shortfalls.
• Merck & Co. Inc. / Organon & Co. — 2007 · $14.4B · Mixed — partial payoff, real shortfalls.
• Sanofi SA / Lexicon Pharmaceuticals Inc. — 2015 · $1.7B · Underwhelmed — fell short of the thesis.
• Mallinckrodt plc / Ikaria, Inc. — 2015 · $2.3B · Underwhelmed — fell short of the thesis.
• Sanofi SA / Alnylam Pharmaceuticals Inc. — 2014 · $700M · Underwhelmed — fell short of the thesis.
• Eli Lilly and Company / Sigilon Therapeutics Inc. — 2018 · $1.8B · Underwhelmed — fell short of the thesis.
• Akcea Therapeutics, Inc. / Ionis Pharmaceuticals, Inc. — 2018 · $1.7B · Did not work — the deal failed to deliver.
• Pfizer Inc. / AstraZeneca PLC — 2014 · $118.0B · Did not work — the deal failed to deliver.
• Novo Nordisk A/S / KBP Biosciences — 2023 · $1.3B · Did not work — the deal failed to deliver.
• Novartis AG / Ionis Pharmaceuticals, Inc. / Akcea Therapeutics, Inc. — 2016 · $1.4B · Did not work — the deal failed to deliver.
• Teva Pharmaceutical Industries Ltd. / Allergan plc (Generics Business) — 2015 · $40.5B · Did not work — the deal failed to deliver.
• Bristol-Myers Squibb Company / Cardioxyl Pharmaceuticals, Inc. — 2015 · $2.1B · Did not work — the deal failed to deliver.
• Allergan plc / ForSight VISION5, Inc. — 2016 · $95M · Did not work — the deal failed to deliver.
• AstraZeneca PLC / Omthera Pharmaceuticals Inc. — 2013 · $443M · Did not work — the deal failed to deliver.
• Daiichi Sankyo Company, Limited / Ranbaxy Laboratories Limited — 2008 · $4.6B · Did not work — the deal failed to deliver.
• Novartis AG / Unnatural Products, Inc. — 2026 · $1.8B
• ARCHIMED (private equity) / Esperion Therapeutics Inc. — 2026 · $1.1B
• GSK plc / 35Pharma Inc. — 2026 · $950M
• Esperion Therapeutics Inc. / Corstasis Therapeutics, Inc. — 2026 · $255M
• Eli Lilly and Company / Ventyx Biosciences, Inc. — 2026 · $1.2B
• Quince Therapeutics, Inc. / Orphai Therapeutics Inc. — 2026
• Novartis AG / Argo Biopharmaceutical Co., Ltd. — 2025 · $5.3B
• CRISPR Therapeutics AG / Sirius Therapeutics, Inc. — 2025 · $95M
• Eli Lilly and Company / Verve Therapeutics, Inc. — 2025 · $1.3B
• Merck & Co. Inc. / Jiangsu Hengrui Pharmaceuticals Co. Ltd. — 2025 · $2.0B
• Novartis AG / Tourmaline Bio, Inc. — 2025 · $1.4B
• AstraZeneca PLC / CSPC Pharmaceutical Group Ltd. — 2024 · $2.0B
• Bayer AG / Dewpoint Therapeutics Inc. — 2024 · $424M
• Eli Lilly and Company / Beam Therapeutics Inc. — 2023 · $600M
• Novo Nordisk A/S / Valo Health, Inc. — 2023 · $4.8B
• AstraZeneca PLC / Neurimmune AG (NI006 license) — 2022 · $760M
• AstraZeneca PLC / Ionis Pharmaceuticals, Inc. — 2021 · $3.6B
• Bayer AG / Asklepios BioPharmaceutical, Inc. (AskBio) — 2020 · $4.0B
• Bayer AG / Recursion Pharmaceuticals, Inc. — 2020 · $1.1B
• Blackstone Group Inc. / Alnylam Pharmaceuticals Inc. — 2020 · $2.0B
• Ionis Pharmaceuticals, Inc. / Akcea Therapeutics, Inc. — 2020 · $500M
• Pfizer Inc. / Akcea Therapeutics / Ionis Pharmaceuticals (AKCEA-ANGPTL3-LRx license) — 2019 · $1.3B
• Novartis AG / IFM Tre, Inc. — 2019 · $1.6B
• Bayer AG / BlueRock Therapeutics LP — 2019 · $600M
• Janssen Pharmaceuticals, Inc. (Johnson & Johnson) / PeptiDream Inc. — 2017 · $1.1B
• Amgen Inc. / Dezima Pharma B.V. — 2015 · $1.6B
• AstraZeneca PLC / Moderna Therapeutics — 2013 · $420M
• Abbott Laboratories / Biocompatibles International plc (cardiovascular stent business) — 2002 · $235M

← Deal Library  ·  Interactive search  ·  How we score deals